Description
The PPP Unit is at the Institute of Biotechnology and Biomedicine of the Autonomous University of Barcelona (IBB-UAB). It counts with the necessary facilities for the design, production, and purification of recombinant proteins. This facility is coordinated by the Nanobiotechnology Group, led by Prof. Antonio Villaverde. It has both highly specialized personnel and the necessary equipment to offer a “tailored” service for the design, production, and purification of recombinant proteins using both prokaryotic and eukaryotic expression systems. Its location allows this service to be linked with other complementary services available within the university (Cell Culture, Cytometry, Production of Antibodies, Microscopy, Proteomic, and Bioinformatic, X-ray crystallography, and Microarray and Sequencing Services), as well as facilitating the management of subsequent uses of the produced protein.
Counts with a laboratory perfectly equipped for the bioproduction of proteins, another with all the necessary equipment for molecular cloning, plus one lab for the purification and characterization, and finally one for cryopreservation.
The PPP Unit has implemented the ISO9001 certification for standard quality control system.
IQNet ISO 9001:2015 Certification PPP
AENOR ISO 9001:2015 Certification PPP
Brochure Unit 1 – PPP
Services
–
FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % THE OF OPENNESS EACH SERVICE
U1. Services & Rates
Other projects
| Ref |
Title |
Funding Organism |
Unit Role |
| PI15/00272 |
Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer. |
Instituto de Salud Carlos III |
Participant |
| BIO2013-41019-P |
ENGINEERING OF PROTEIN NANOPARTICLES FOR THE DIRECT DELIVERY OF THERAPEUTIC PROTEINS AND NUCLEIC ACIDS |
MINECO |
Participant |
| 2014SGR-132 |
Basic and Applied Microbiology |
AGAUR |
Participant |
| BIO2016-76063-R |
DEVELOPMENT OF NONOSTRUCTURED PROTEIN TOXINS AND POISONS FOR THE TREATMENT OF CXCR4 + CANCERES |
MINECO |
Working package |
| RTC-2014-2207-1 |
TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases |
MINECO |
Participant |
| Marato 416/C/2030TV32013-132031 |
Genotoxic nanoparticles targeting colorectal cancer stem cells |
Marato TV3 |
Participant |
Publications
2016
- Corchero J.L. Eukaryotic aggresomes: from a model of conformational diseases to an emerging type of immobilized biocatalyzers. Applied Microbiology and Biotechnology. 2016;100(2):559-569.
- Saccardo P., Corchero J.L., Ferrer-Miralles N.. Tools to cope with difficult-to-express proteins. Applied Microbiology and Biotechnology. 2016;:1-9.
- Torrealba D., Seras-Franzoso J., Mamat U., Wilke K., Villaverde A., Roher N. et al. Complex particulate biomaterials as immunostimulant-delivery platforms. PLoS ONE. 2016;11(10)
- Cano-Garrido O., Sanchez-Chardi A., Pares S., Giro I., Tatkiewicz W.I., Ferrer-Miralles N. et al. Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. Acta Biomaterialia. 2016;43:230-239.
- Serna N., Cespedes M.V., Saccardo P., Xu Z., Unzueta U., Alamo P. et al. Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine. 2016;12(5):1241-1251.
- Rueda F., Gasser B., Sanchez-Chardi A., Roldan M., Villegas S., Puxbaum V. et al. Functional inclusion bodies are produced in the yeast Pichia pastoris. Microbial Cell Factories. 2016;15(1)
- Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
- Céspedes MV, Unzueta U, Álamo P, Gallardo A, Sala R, Casanova I et al. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4+ colorectal cancer models.Nanomedicine : nanotechnology, biology, and medicine. 2016;12(7)
- Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.
News U1
12 Sep
Prof. Villaverde and Prof. Vázquez present nanomedicine advances in cancer therapy and drug delivery at Nanomat 2025, supported by NANBIOSIS. Barcelona, September, 2025 — Two leading scientists from the Autonomous University of Barcelona (UAB), Prof. Antonio Villaverde and Prof. Esther Vázquez, participated last week as invited speakers at Nanomat 2025, an international conference on nanomaterials and nanobiotechnology. The event brought together experts in nanomedicine, healthcare, energy, and advanced materials to foster scientific debate, collaboration, and innovation. Targeted Protein Nanoparticles for Cancer Therapy Prof. Esther Vázquez Gómez, Senior Researcher at the Institute of Biotechnology and Biomedicine (IBB-UAB) and Principal Investigator of[...]
11 Sep
NANBIOSIS supports IdiPAZ project to develop protein-based therapy from extracellular vesicles to improve recovery after brain hemorrhage. Barcelona, September, 2025 — The Protein Production Platform (PPP, NANBIOSIS Unit 1) has joined an innovative translational research project led by the Neurology and Cerebrovascular Diseases Group at the Health Research Institute of Hospital Universitario La Paz (IdiPAZ). The project, funded by the Instituto de Salud Carlos III (ISCIII) under grant PI23/00436, focuses on the development of a new protein-based treatment to improve recovery after brain hemorrhage. The strategy involves the administration of encapsulated therapeutic proteins, representing a novel approach to enhance functiona[...]
23 May
“Fabry Connections” united patients, researchers, and clinicians at ICMAB to advance Fabry disease care and nanomedicine-based therapies. Barcelona, april 2025. On Tuesday, 29 April 2025, the Institute of Materials Science of Barcelona (ICMAB, CSIC) hosted the event “Fabry Connections: Science, Patients, and Future”, bringing together around 50 participants including researchers, clinicians, patients, and patient association representatives. The event aimed to create a multidisciplinary platform for sharing knowledge and advancing the future of Fabry disease research and treatment. Attendees at the Fabry Connections event at ICMAB | ICMAB-CSIC As we announced back in february 28, this special event was held within Fabry Diseas[...]
22 Apr
Researchers use a bacterial toxin domain to boost drug delivery across skin barriers, opening new paths for non-invasive protein-based therapies. Barcelona, april 2025. Researchers from NANBIOSIS Units at UAB and IR Sant Pau develop innovative strategy for transdermal protein drug delivery using recombinant proteins. In a major advance in drug delivery research, scientists from NANBIOSIS Unit 1 and Unit 18 at the Universitat Autònoma de Barcelona (UAB) and the Institut de Recerca Sant Pau, affiliated with the CIBER-BBN network, have demonstrated a novel method to increase the permeability of epithelial tissues. By harnessing the non-toxic functional domain of a bacteria[...]
15 Apr
Researchers from NANBIOSIS co-author a new study showcasing an innovative approach to protein-based biomaterials for drug delivery and regenerative medicine. Barcelona, april 2025. A recent publication in the International Journal of Biological Macromolecules highlights the cutting-edge work of scientists from Unit 1 (Protein Production Platform, PPP) and Unit 18 (Nanotoxicology Unit) of NANBIOSIS, under the leadership of Prof. Antonio Villaverde and Prof. Ramón Mangues, respectively. The study, entitled “Surpassing protein specificity in biomimetics of bacterial amyloids” (DOI: 10.1016/j.ijbiomac.2025.139635), explores the development of artificial protein granules with promising applications in biomedicine. A Novel Approach to Biomimetic Materials The research introduces a[...]
31 Mar
Breakthrough nanotherapy targets MSS colorectal cancer, inducing pyroptosis and immune activation. NANBIOSIS Units 1 and Unit 18 played a key role. Barcelona, march 2024. For this World Colorectal Cancer Day, researchers from Dr. Mangues’ group (CB06/01/1031), in which NANBIOSIS Unit 18 is integrated, have published just last month a groundbreaking study on a novel targeted nanotherapy for colorectal cancer. Conducted in collaboration with three CIBER research groups across two thematic areas (BBN and ER), this research highlights the potential of CXCR4-targeted nanotoxic therapy to combat microsatellite stable (MSS) colorectal cancer, a subtype known for its resistance to immune checkpoint inhibitors[...]
10 Dec
NANBIOSIS’s Protein Production Platform showcased innovations in protein engineering at PEGS Europe 2024, featuring talks, posters, and session moderation. Barcelona, november 2024. Last month, the NBT group and Unit 1 of NANBIOSIS (Protein Production Platform, PPP), from CIBER-BBN and IBB-UAB, was invited once again to participate in the prestigious PEGS Europe conference. PEGS Europe, a prestigous conference This year, the 16th PEGS Europe conference was held in Barcelona from November 5th to 7th. PEGS, or the Protein & Antibody Engineering Summit, is organized by the Cambridge Healthtech Institute (CHI) and is renowned for its focus on protein engineering and its[...]
18 Nov
The PPP advances antimicrobial peptide research, forging partnerships to combat antibiotic resistance and prevent medical device-related infections. Barcelona, october 2024. During Antibiotic Awareness Week, we spotlight the Protein Production Platform (PPP) at NANBIOSIS Unit 1 for its pivotal role in combating antimicrobial resistance. At the recent UAB Innovation Fair, the PPP showcased its cutting-edge technologies and established collaborations with experts in bacterial biofilms and nanomaterials. Together, they aim to develop innovative antimicrobial peptides as alternatives to traditional antibiotics, targeting nosocomial infections linked to medical devices. These efforts underscore the critical importance of advancing research and partnerships to address one of[...]
